Changes in the classification and management of skin and soft tissue infections

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 232-234

  Koerner, Roland ^a   Johnson, Alan P ^b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Empirical; Severity; SSTIs

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; TEICOPLANIN;

ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; MORTALITY; SCORING SYSTEM; SEPSIS; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION;

AMBULATORY CARE FACILITIES; ANTI-BACTERIAL AGENTS; HUMANS; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78651462635     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq443     Document Type: Article

References (14)

1. Morris AD. Cellulitis and erysipelas. BMJ Clin Evid 2007; 12: 1708.
2. Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl S1: i3-17.
3. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008; 19: 173-84.
4. CREST (Clinical Resource Efficiency Support Team). CREST (Clinical Resource Efficiency Support Team) Guidelines on the Management of Cellulitis in Adults. DHSS Northern Ireland, 2005; 1-31.
5. Marwick C, Broomhall J, McCowan C, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother 2011; 66: 387-397.
6. Paterson R, MacLeod DC, Thetford D, et al. Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. Clin Med 2006; 6: 281-4.
7. Jorup-Ronstrom C, Britton S, Gavlevik A, et al. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12: 390-4.
8. Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160-9.
9. Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemother 2009; 64: 447-53.
10. Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009; 34 Suppl 1: S24-9.
11. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008; 62 Suppl 3: iii15-23.
12. Lamont E, Seaton RA, Macpherson M, et al. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother 2009; 64: 181-7.
13. Nathwani D, Barlow GD, Adjukiewicz K, et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother 2003; 51: 391-6.
14. General Medical Council. Tomorrow's Doctors. http://www.gmc-uk.org/education/undergraduate/tomorrows_doctors.asp. (18 October 2010, date last accessed).